Literature DB >> 18690857

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance.

J Rosemary1, C Adithan.   

Abstract

CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize about 18% of currently available drugs. Some of the important groups of drugs that are metabolized by them are antihypertensives, hypoglycemics, anticonvulsants, antiulcer drugs etc. Genes encoding these enzymes are polymorphically expressed. Thirty variant alleles for CYP2C9 and 21 for CYP2C19 have been reported. The frequencies of these polymorphic alleles show marked inter-ethnic variation. Several reports have been published showing the clinical importance of this polymorphism. This review summarizes the currently available important information on this topic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18690857     DOI: 10.2174/157488407779422302

Source DB:  PubMed          Journal:  Curr Clin Pharmacol        ISSN: 1574-8847


  38 in total

1.  Stereoselective pharmacokinetics of stable isotope (+/-)-[13C]-pantoprazole: Implications for a rapid screening phenotype test of CYP2C19 activity.

Authors:  David L Thacker; Anil Modak; Phuong D Nguyen; David A Flockhart; Zeruesenay Desta
Journal:  Chirality       Date:  2011-09-20       Impact factor: 2.437

2.  Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood.

Authors:  Ersin Gumus; Ozgur Karaca; Melih O Babaoglu; Gökhan Baysoy; Necati Balamtekin; Hulya Demir; Nuray Uslu; Atilla Bozkurt; Aysel Yuce; Umit Yasar
Journal:  Eur J Clin Pharmacol       Date:  2011-11-11       Impact factor: 2.953

Review 3.  Reaction phenotyping: current industry efforts to identify enzymes responsible for metabolizing drug candidates.

Authors:  Timothy W Harper; Patrick J Brassil
Journal:  AAPS J       Date:  2008-04-05       Impact factor: 4.009

4.  Genetic variability of CYP2C19 in a Mexican population: contribution to the knowledge of the inheritance pattern of CYP2C19*17 to develop the ultrarapid metabolizer phenotype.

Authors:  Alma Faviola Favela-Mendoza; Gabriela Martinez-Cortes; Marcelo Hernandez-Zaragoza; Joel Salazar-Flores; Jose Francisco Muñoz-Valle; Victor Manuel Martinez-Sevilla; Noemi Yolanda Velazquez-Suarez; Hector Rangel-Villalobos
Journal:  J Genet       Date:  2015-03       Impact factor: 1.166

5.  Maintenance therapy of gastroesophageal reflux disease.

Authors:  Akihito Nagahara; Mariko Hojo; Daisuke Asaoka; Sumio Watanabe
Journal:  Clin J Gastroenterol       Date:  2010-02-19

6.  Is (+)-[13C]-pantoprazole better than (±)-[13C]-pantoprazole for the breath test to evaluate CYP2C19 enzyme activity?

Authors:  David L Thacker; Anil Modak; David A Flockhart; Zeruesenay Desta
Journal:  J Breath Res       Date:  2012-12-21       Impact factor: 3.262

Review 7.  Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy.

Authors:  Rajeev K Mehlotra; Cara N Henry-Halldin; Peter A Zimmerman
Journal:  Pharmacogenomics       Date:  2009-03       Impact factor: 2.533

8.  No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma.

Authors:  Annette J Vangsted; Karen Søeby; Tobias W Klausen; Niels Abildgaard; Niels F Andersen; Peter Gimsing; Henrik Gregersen; Ulla Vogel; Thomas Werge; Henrik B Rasmussen
Journal:  BMC Cancer       Date:  2010-08-04       Impact factor: 4.430

9.  Genetic testing for CYP450 polymorphisms to predict response to clopidogrel: current evidence and test availability. Application: pharmacogenomics.

Authors:  Renée M Ned Mmsc Phd
Journal:  PLoS Curr       Date:  2010-09-20

10.  Role of pharmacogenomics in drug discovery and development.

Authors:  A Surendiran; S C Pradhan; C Adithan
Journal:  Indian J Pharmacol       Date:  2008-08       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.